Literature DB >> 33751255

New hemostatic technique with combined use of Hydrofit® and Surgicel®: an in vitro and in vivo study.

Masaaki Naganuma1, Keisuke Kanda1, Konosuke Sasaki1, Kay Maeda1, Koki Ito1, Shintaro Katahira1, Yoshikatsu Saiki2.   

Abstract

We developed an effective hemostatic technique using Hydrofit® and Surgicel® simultaneously. The aim of this study was to demonstrate the hemostatic efficacy of the Hydrofit® and Surgicel® combination technique through an in vitro experiment and to elucidate mid-term consequences of the combined components through an in vivo experiment. For the in vitro experiment, a closed circuit using a heparin-coated cardiopulmonary bypass circuit and a prosthetic graft was created. The amount of bleeding from the prosthetic graft was measured, and the following three hemostatic methods were applied: only gauze compression in control group, Hydrofit® application in Hydrofit group, Surgicel® spread Hydrofit® application in Hydrofit and Surgicel (HS) group, respectively. In the in vivo experiment, Hydrofit® and/or Surgicel® were implanted under skin on the back of rats (n = 10) at 4 points. In the control group, only an incision was made; in the Hydrofit, Surgicel, and HS groups, Hydrofit® and/or Surgicel® was implanted. One and three months later, each of the five rats were killed and in each section histopathologic examination was carried out. In the in vitro experiment, the amount of bleeding was 7.84 ± 1.08, 2.26 ± 1.02, and 0.87 ± 0.38 ml in the control, Hydrofit, and HS groups, respectively. The amount of bleeding in the HS group was more suppressed than in the Hydrofit group (p = 0.012). In the in vivo experiment, the maximal depth diameter of each remaining hemostatic sealant was measured. After 3 months, the diameter was 0, 2289.0 ± 768.2, 3850.3 ± 935.8 μm in Surgicel, Hydrofit and HS groups, respectively. The diameter was significantly increased in the HS group compared with the Surgicel and Hydrofit groups (p < 0.001, respectively,). In conclusion, the combination of Hydrofit® and Surgicel® was effective in achieving hemostasis. The remnants of Hydrofit® and Surgicel® were present for a long time in the tissues which could compress the surrounding tissue.

Entities:  

Keywords:  Aortic surgery; Hemostasis; Hydrofit®; Surgical sealant; Surgicel®

Year:  2021        PMID: 33751255     DOI: 10.1007/s10047-021-01257-5

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  2 in total

1.  A novel elastomeric surgical adhesive: design, properties, and in vivo performances.

Authors:  T Matsuda; T Itoh; T Yamaguchi; H Iwata; K Hayashi; S Uemura; T Ando; S Adachi; N Nakajima
Journal:  ASAIO Trans       Date:  1986 Jul-Sep

2.  [Development of hemostatic sealant for arterial anastomosis; clinical application].

Authors:  Shigeki Morita; Takehisa Matsuda; Masataka Eto; Shinichiro Oda; Ryuji Tominaga
Journal:  Kyobu Geka       Date:  2013-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.